We read with great interest the article by BinHumaid and colleagues [1], who report that positive preoperative circulating tumor DNA (ctDNA) status in 93 patients with high-grade pT1 non–muscle-invasive bladder cancer (NMIBC) was strongly associated with significantly worse overall and disease-specific survival. This elegant and innovative work extends the prognostic relevance of ctDNA beyond muscle-invasive disease and suggests that a subset of NMIBC cases harbor biologically aggressive and systemically detectable disease.
We read with great interest the article by BinHumaid and colleagues [1], who report that positive preoperative circulating tumor DNA (ctDNA) status in 93 patients with high-grade pT1 non–muscle-invasive bladder cancer (NMIBC) was strongly associated with significantly worse overall and disease-specific survival. This elegant and innovative work extends the prognostic relevance of ctDNA beyond muscle-invasive disease and suggests that a subset of NMIBC cases harbor biologically aggressive and systemically detectable disease.